Allogene Therapeutics Inc

Allogene Therapeutics’ insider sales and massive new equity grants signal a strategic shift—executives cover taxes while betting on future CAR‑T growth, raising questions about dilution, liquidity and payer‑reimbursement success.

Allogene Therapeutics’ insider sell‑to‑cover by EVP R&D is a routine tax move that keeps the company’s promising CAR‑T pipeline intact and signals no shift in strategy.